Resveratrol engages AMPK to attenuate ERK and mTOR signaling in sensory neurons and inhibits incision-induced acute and chronic pain

Molecular Pain

Volumn 8, Issue , 2012, Pages

  Tillu, Dipti V ^a   Melemedjian, Ohannes K ^a   Asiedu, Marina N ^a   Qu, Ning ^a   De Felice, Milena ^a   Dussor, Gregory ^a,b   Price, Theodore J ^a,b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAY 10602; ENZYME ACTIVATOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROSTAGLANDIN E2; RESVERATROL; SIRTUIN; SIRTUIN 1; UNCLASSIFIED DRUG; INITIATION FACTOR 4F; SIRT1 PROTEIN, MOUSE; STILBENE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC PAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; INCISION; MALE; MOUSE; NOCICEPTION; NONHUMAN; PAIN; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROTEIN FUNCTION; SENSORY NERVE CELL; SIGNAL TRANSDUCTION; TRANSLATION REGULATION; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HYPERALGESIA; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PATHOLOGY; PROTEIN SYNTHESIS; SENSORY RECEPTOR; TIME; TRIGEMINUS GANGLION;

ACUTE PAIN; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CHRONIC PAIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EUKARYOTIC INITIATION FACTOR-4F; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HYPERALGESIA; INTERLEUKIN-6; MALE; MICE; MICE, INBRED ICR; PAIN, POSTOPERATIVE; PROTEIN BIOSYNTHESIS; SENSORY RECEPTOR CELLS; SIGNAL TRANSDUCTION; SIRTUIN 1; STILBENES; TIME FACTORS; TOR SERINE-THREONINE KINASES; TRIGEMINAL GANGLION;

EID: 84856045492     PISSN: None     EISSN: 17448069     Source Type: Journal    
DOI: 10.1186/1744-8069-8-5     Document Type: Article

References (64)

1. Aasvang EK, Gmaehle E, Hansen JB, Gmaehle B, Forman JL, Schwarz J, Bittner R, Kehlet H. Predictive risk factors for persistent postherniotomy pain. Anesthesiology 2010, 112(4):957-969. 10.1097/ALN.0b013e3181d31ff8, 20234307.
2. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet 2006, 367(9522):1618-1625. 10.1016/S0140-6736(06)68700-X, 16698416.
3. Perkins FM, Kehlet H. Chronic pain as an outcome of surgery. A review of predictive factors. Anesthesiology 2000, 93(4):1123-1133. 10.1097/00000542-200010000-00038, 11020770.
4. Apfelbaum JL, Chen C, Mehta SS, Gan TJ. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg 2003, 97(2):534-540. table of contents, 10.1213/01.ANE.0000068822.10113.9E, 12873949.
5. Pavlin DJ, Chen C, Penaloza DA, Polissar NL, Buckley FP. Pain as a factor complicating recovery and discharge after ambulatory surgery. Anesth Analg 2002, 95(3):627-634.
6. Holzheimer RG, Steinmetz W. Local and systemic concentrations of pro- and anti-inflammatory cytokines in human wounds. Eur J Med Res 2000, 5(8):347-355.
7. Notarnicola A, Moretti L, Tafuri S, Vacca A, Marella G, Moretti B. Postoperative pain monitor after total knee replacement. Musculoskelet Surg 2011, 95(1):19-24. 10.1007/s12306-011-0102-2, 21472530.
8. Pandazi A, Kapota E, Matsota P, Paraskevopoulou P, Dervenis C, Kostopanagiotou G. Preincisional versus postincisional administration of parecoxib in colorectal surgery: effect on postoperative pain control and cytokine response. A randomized clinical trial World J Surg 2010, 34(10):2463-2469.
9. Lin E, Calvano SE, Lowry SF. Inflammatory cytokines and cell response in surgery. Surgery 2000, 127(2):117-126. 10.1067/msy.2000.101584, 10686974.
10. Bryan D, Walker KB, Ferguson M, Thorpe R. Cytokine gene expression in a murine wound healing model. Cytokine 2005, 31(6):429-438. 10.1016/j.cyto.2005.06.015, 16102971.
11. Sato Y, Ohshima T. The expression of mRNA of proinflammatory cytokines during skin wound healing in mice: a preliminary study for forensic wound age estimation (II). Int J Legal Med 2000, 113(3):140-145. 10.1007/s004140050285, 10876984.
12. Sahbaie P, Shi X, Guo TZ, Qiao Y, Yeomans DC, Kingery WS, Clark JD. Role of substance P signaling in enhanced nociceptive sensitization and local cytokine production after incision. Pain 2009, 145(3):341-349. 10.1016/j.pain.2009.06.037, 2746201, 19660865.
13. Liang D, Shi X, Qiao Y, Angst MS, Yeomans DC, Clark JD. Chronic morphine administration enhances nociceptive sensitivity and local cytokine production after incision. Mol Pain 2008, 4:7. 10.1186/1744-8069-4-7, 2279109, 18294378.
14. Clark JD, Shi X, Li X, Qiao Y, Liang D, Angst MS, Yeomans DC. Morphine reduces local cytokine expression and neutrophil infiltration after incision. Mol Pain 2007, 3:28. 10.1186/1744-8069-3-28, 2096620, 17908329.
15. Quarta S, Vogl C, Constantin CE, Uceyler N, Sommer C, Kress M. Genetic evidence for an essential role of neuronally expressed IL-6 signal transducer gp130 in the induction and maintenance of experimentally induced mechanical hypersensitivity in vivo and in vitro. Mol Pain 2011, 7:73. 10.1186/1744-8069-7-73, 3197546, 21951917.
16. Andratsch M, Mair N, Constantin CE, Scherbakov N, Benetti C, Quarta S, Vogl C, Sailer CA, Uceyler N, Brockhaus J, et al. A key role for gp130 expressed on peripheral sensory nerves in pathological pain. The Journal of neuroscience: the official journal of the Society for Neuroscience 2009, 29(43):13473-13483.
17. Melemedjian OK, Asiedu MN, Tillu DV, Peebles KA, Yan J, Ertz N, Dussor GO, Price TJ. IL-6- and NGF-Induced Rapid Control of Protein Synthesis and Nociceptive Plasticity via Convergent Signaling to the eIF4F Complex. J Neurosci 2010, 30(45):15113-15123. 10.1523/JNEUROSCI.3947-10.2010, 3056511, 21068317.
18. Melemedjian OK, Asiedu MN, Tillu DV, Sanoja R, Yan J, Lark A, Khoutorsky A, Johnson J, Peebles KA, Lepow T, et al. Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. Mol Pain 2011, 7:70. 10.1186/1744-8069-7-70, 3186752, 21936900.
19. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007, 8(10):774-785. 10.1038/nrm2249, 17712357.
20. Kim J, Yoon MY, Choi SL, Kang I, Kim SS, Kim YS, Choi YK, Ha J. Effects of stimulation of AMP-activated protein kinase on insulin-like growth factor 1- and epidermal growth factor-dependent extracellular signal-regulated kinase pathway. J Biol Chem 2001, 276(22):19102-19110. 10.1074/jbc.M011579200, 11262401.
21. Dasgupta B, Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USA 2007, 104(17):7217-7222. 10.1073/pnas.0610068104, 1855377, 17438283.
22. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425(6954):191-196. 10.1038/nature01960, 12939617.
23. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M, Sinclair D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004, 430(7000):686-689. 10.1038/nature02789, 15254550.
24. Viswanathan M, Kim SK, Berdichevsky A, Guarente L. A role for SIR-2.1 regulation of ER stress response genes in determining C. elegans life span. Dev Cell 2005, 9(5):605-615. 10.1016/j.devcel.2005.09.017, 16256736.
25. Jarolim S, Millen J, Heeren G, Laun P, Goldfarb DS, Breitenbach M. A novel assay for replicative lifespan in Saccharomyces cerevisiae. FEMS Yeast Res 2004, 5(2):169-177. 10.1016/j.femsyr.2004.06.015, 15489200.
26. Beher D, Wu J, Cumine S, Kim KW, Lu SC, Atangan L, Wang M. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 2009, 74(6):619-624. 10.1111/j.1747-0285.2009.00901.x, 19843076.
27. Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, Griffith D, Griffor M, Loulakis P, Pabst B, et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 2010, 285(11):8340-8351. 10.1074/jbc.M109.088682, 2832984, 20061378.
28. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444(7117):337-342. 10.1038/nature05354, 17086191.
29. Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, Wierzbicki M, Verbeuren TJ, Cohen RA. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 2006, 55(8):2180-2191. 10.2337/db05-1188, 16873680.
30. Dasgupta B, Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USA 2007, 104(17):7217-7222. 10.1073/pnas.0610068104, 1855377, 17438283.
31. Um JH, Park SJ, Kang H, Yang S, Foretz M, McBurney MW, Kim MK, Viollet B, Chung JH. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010, 59(3):554-563. 10.2337/db09-0482, 2828647, 19934007.
32. Raught B, Gingras AC, Gygi SP, Imataka H, Morino S, Gradi A, Aebersold R, Sonenberg N. Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI. EMBO J 2000, 19(3):434-444. 10.1093/emboj/19.3.434, 305580, 10654941.
33. Harris TE, Chi A, Shabanowitz J, Hunt DF, Rhoads RE, Lawrence JC. mTOR-dependent stimulation of the association of eIF4G and eIF3 by insulin. EMBO J 2006, 25(8):1659-1668. 10.1038/sj.emboj.7601047, 1440840, 16541103.
34. Berset C, Trachsel H, Altmann M. The TOR (target of rapamycin) signal transduction pathway regulates the stability of translation initiation factor eIF4G in the yeast Saccharomyces cerevisiae. Proc Natl Acad Sci USA 1998, 95(8):4264-4269. 10.1073/pnas.95.8.4264, 22477, 9539725.
35. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009, 136(4):731-745. 10.1016/j.cell.2009.01.042, 19239892.
36. Beretta L, Gingras AC, Svitkin YV, Hall MN, Sonenberg N. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J 1996, 15(3):658-664. 449984, 8599949.
37. Nayagam VM, Wang X, Tan YC, Poulsen A, Goh KC, Ng T, Wang H, Song HY, Ni B, Entzeroth M, et al. SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J Biomol Screen 2006, 11(8):959-967. 10.1177/1087057106294710, 17099246.
38. Asiedu MN, Tillu DV, Melemedjian OK, Shy A, Sanoja R, Bodell B, Ghosh S, Porreca F, Price TJ. Spinal protein kinase M zeta underlies the maintenance mechanism of persistent nociceptive sensitization. J Neurosci 2011, 31(18):6646-6653. 10.1523/JNEUROSCI.6286-10.2011, 3090264, 21543593.
39. Price TJ, Rashid MH, Millecamps M, Sanoja R, Entrena JM, Cervero F. Decreased nociceptive sensitization in mice lacking the fragile X mental retardation protein: role of mGluR1/5 and mTOR. J Neurosci 2007, 27(51):13958-13967. 10.1523/JNEUROSCI.4383-07.2007, 2206543, 18094233.
40. Jimenez-Diaz L, Geranton SM, Passmore GM, Leith JL, Fisher AS, Berliocchi L, Sivasubramaniam AK, Sheasby A, Lumb BM, Hunt SP. Local translation in primary afferent fibers regulates nociception. PLoS One 2008, 3(4):e1961. 10.1371/journal.pone.0001961, 2276314, 18398477.
41. Geranton SM, Jimenez-Diaz L, Torsney C, Tochiki KK, Stuart SA, Leith JL, Lumb BM, Hunt SP. A rapamycin-sensitive signaling pathway is essential for the full expression of persistent pain states. J Neurosci 2009, 29(47):15017-15027. 10.1523/JNEUROSCI.3451-09.2009, 2830115, 19940197.
42. Obara I, Tochiki KK, Geranton SM, Carr FB, Lumb BM, Liu Q, Hunt SP. Systemic inhibition of the mammalian target of rapamycin (mTOR) pathway reduces neuropathic pain in mice. Pain 2011, 152(11):2582-2595. 10.1016/j.pain.2011.07.025, 21917376.
43. Ji RR, Gereau R, Malcangio M, Strichartz GR. MAP kinase and pain. Brain Res Rev 2009, 60(1):135-148. 10.1016/j.brainresrev.2008.12.011, 2666786, 19150373.
44. Asiedu MN, Tillu DV, Melemedjian OK, Shy A, Sanoja R, Bodell B, Ghosh S, Porreca F, Price TJ. Spinal protein kinase M zeta underlies the maintenance mechanism of persistent nociceptive sensitization. The Journal of neuroscience: the official journal of the Society for Neuroscience 2011, 31(18):6646-6653.
45. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011, 12(1):21-35. 10.1038/nrm3025, 21157483.
46. Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M, Dickinson R, Adler A, Gagne G, Iyengar R, et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 2006, 3(6):403-416. 10.1016/j.cmet.2006.05.005, 16753576.
47. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005, 310(5754):1642-1646. 10.1126/science.1120781, 3074427, 16308421.
48. Ouyang J, Parakhia RA, Ochs RS. Metformin activates AMP kinase through inhibition of AMP deaminase. J Biol Chem 2011, 286(1):1-11. 10.1074/jbc.M110.121806, 3012963, 21059655.
49. Corradetti MN, Inoki K, Bardeesy N, DePinho RA, Guan KL. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev 2004, 18(13):1533-1538. 10.1101/gad.1199104, 443516, 15231735.
50. Tzatsos A, Tsichlis PN. Energy depletion inhibits phosphatidylinositol 3-kinase/Akt signaling and induces apoptosis via AMP-activated protein kinase-dependent phosphorylation of IRS-1 at Ser-794. J Biol Chem 2007, 282(25):18069-18082. 10.1074/jbc.M610101200, 17459875.
51. Argetsinger LS, Hsu GW, Myers MG, Billestrup N, White MF, Carter-Su C. Growth hormone, interferon-gamma, and leukemia inhibitory factor promoted tyrosyl phosphorylation of insulin receptor substrate-1. J Biol Chem 1995, 270(24):14685-14692. 10.1074/jbc.270.24.14685, 7782332.
52. Reichling DB, Levine JD. Critical role of nociceptor plasticity in chronic pain. Trends Neurosci 2009, 32(12):611-618. 10.1016/j.tins.2009.07.007, 2787756, 19781793.
53. Campillo A, Cabanero D, Romero A, Garcia-Nogales P, Puig MM. Delayed postoperative latent pain sensitization revealed by the systemic administration of opioid antagonists in mice. Eur J Pharmacol 2011, 657(1-3):89-96. 10.1016/j.ejphar.2011.01.059, 21300053.
54. Shin SM, Cho IJ, Kim SG. Resveratrol protects mitochondria against oxidative stress through AMP-activated protein kinase-mediated glycogen synthase kinase-3beta inhibition downstream of poly(ADP-ribose)polymerase-LKB1 pathway. Mol Pharmacol 2009, 76(4):884-895. 10.1124/mol.109.058479, 19620254.
55. Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, Jang M, Pezzuto JM, Dannenberg AJ. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 1998, 273(34):21875-21882. 10.1074/jbc.273.34.21875, 9705326.
56. Utreras E, Terse A, Keller J, Iadarola MJ, Kulkarni AB. Resveratrol inhibits Cdk5 activity through regulation of p35 expression. Mol Pain 2011, 7:49. 10.1186/1744-8069-7-49, 3212955, 21736731.
57. Kim HI, Kim TH, Song JH. Resveratrol inhibits Na + currents in rat dorsal root ganglion neurons. Brain Res 2005, 1045(1-2):134-141. 10.1016/j.brainres.2005.03.019, 15910771.
58. Torres-Lopez JE, Ortiz MI, Castaneda-Hernandez G, Alonso-Lopez R, Asomoza-Espinosa R, Granados-Soto V. Comparison of the antinociceptive effect of celecoxib, diclofenac and resveratrol in the formalin test. Life Sci 2002, 70(14):1669-1676. 10.1016/S0024-3205(02)01491-1, 11991254.
59. Gentilli M, Mazoit JX, Bouaziz H, Fletcher D, Casper RF, Benhamou D, Savouret JF. Resveratrol decreases hyperalgesia induced by carrageenan in the rat hind paw. Life Sci 2001, 68(11):1317-1321. 10.1016/S0024-3205(00)01018-3, 11233998.
60. Wuertz K, Quero L, Sekiguchi M, Klawitter M, Nerlich A, Konno S, Kikuchi S, Boos N. The red wine polyphenol resveratrol shows promising potential for the treatment of nucleus pulposus-mediated pain in vitro and in vivo. Spine 2011, 36(21):E1373-E1384. 10.1097/BRS.0b013e318221e655, 21587103.
61. Larrosa M, Azorin-Ortuno M, Yanez-Gascon MJ, Garcia-Conesa MT, Tomas-Barberan F, Espin JC. Lack of effect of oral administration of resveratrol in LPS-induced systemic inflammation. Eur J Nutr 2011, 50(8):673-678. 10.1007/s00394-011-0178-3, 21373948.
62. Aasvang EK, Hansen JB, Malmstrom J, Asmussen T, Gennevois D, Struys MM, Kehlet H. The effect of wound instillation of a novel purified capsaicin formulation on postherniotomy pain: a double-blind, randomized, placebo-controlled study. Anesth Analg 2008, 107(1):282-291. 10.1213/ane.0b013e31816b94c9, 18635499.
63. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994, 53(1):55-63. 10.1016/0165-0270(94)90144-9, 7990513.
64. Banik RK, Woo YC, Park SS, Brennan TJ. Strain and sex influence on pain sensitivity after plantar incision in the mouse. Anesthesiology 2006, 105(6):1246-1253. 10.1097/00000542-200612000-00025, 17122588.